NASDAQ:RARX - Ra Pharmaceuticals Stock Price, Forecast & News

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

Ra Pharmaceuticals Inc (NASDAQ:RARX) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.55) EPS for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.05. The business had revenue of $3 million for the quarter. View Ra Pharmaceuticals' Earnings History.

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ra Pharmaceuticals.

11 Wall Street analysts have issued 1-year price targets for Ra Pharmaceuticals' stock. Their forecasts range from $42.00 to $49.00. On average, they expect Ra Pharmaceuticals' stock price to reach $47.50 in the next year. This suggests a possible upside of 1.5% from the stock's current price. View Analyst Price Targets for Ra Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 11 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ra Pharmaceuticals.

News stories about RARX stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ra Pharmaceuticals earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Ra Pharmaceuticals.

Ra Pharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 5,490,000 shares, an increase of 30.1% from the December 31st total of 4,220,000 shares. Based on an average trading volume of 817,000 shares, the days-to-cover ratio is currently 6.7 days. Currently, 14.1% of the shares of the company are sold short. View Ra Pharmaceuticals' Current Options Chain.

Some companies that are related to Ra Pharmaceuticals include Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Amarin (AMRN), Dr.Reddy's Laboratories (RDY), Horizon Therapeutics (HZNP), The Medicines (MDCO), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO) and Evotec (EVTCY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Amarin (AMRN), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), Fate Therapeutics (FATE), Galmed Pharmaceuticals (GLMD), Immunomedics (IMMU), Novavax (NVAX), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

(RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Ra Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Syquant Capital Sas (0.28%), Calamos Advisors LLC (0.23%), Vertex One Asset Management Inc. (0.22%) and Zurcher Kantonalbank Zurich Cantonalbank (0.00%). Company insiders that own Ra Pharmaceuticals stock include Alonso Ricardo, Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp, Rajeev M Shah, Ramin Farzaneh-Far and Simon Read. View Institutional Ownership Trends for Ra Pharmaceuticals.

RARX stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Ra Pharmaceuticals company stock in the last year include Alonso Ricardo, Ramin Farzaneh-Far and Simon Read. View Insider Buying and Selling for Ra Pharmaceuticals.

RARX stock was acquired by a variety of institutional investors in the last quarter, including Syquant Capital Sas, Calamos Advisors LLC and Vertex One Asset Management Inc.. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RARX stock can currently be purchased for approximately $46.78.

Ra Pharmaceuticals has a market capitalization of $2.21 billion and generates $2.50 million in revenue each year. The company earns $-64,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe.View Additional Information About Ra Pharmaceuticals.

The official website for Ra Pharmaceuticals is http://www.rapharma.com/.

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]